include depth of tumor invasion into the intestinal wall and presence of nodal metastases, 5 performance status, co-morbid conditions such as diabetes, the presence of venous or lymphatic invasion, and tumor grade. 6, 7 Additional complexity in personalized prognostication lies in newly identified biologic, genetic and other molecular information,
which have yet a validated role for colon or rectal cancer. [8] [9] [10] [11] Clinicians and patients are continually challenged as to how to best incorporate established and novel prognostic information alongside anatomic stage into a single, individualized estimate of outcome. Clinical prognostication tools, traditionally based on statistical regression models, are one method of combining prognostic information that avoids further stratification of the TNM staging system, which is based on an inelastic mathematical bin model. 12, 13 If appropriately developed and validated, these tools have the potential to integrate and personalize the prognostic information available for individual patients and provide refined risk estimates for application to uncertain clinical management scenarios. 14 The landscape of prognostication tool quality and clinical relevance is currently unknown in colorectal cancer. The Molecular Modellers
Working Group (MMWG) of the American Joint Committee on Cancer (AJCC) was formed to understand how information beyond stage could be used to individualize survival prognostication and personalize patient management. The MMWG chose to review the quality and usability of currently available clinical prognostic tools that predict survival in colorectal and four other cancers as their first task. [15] [16] [17] The work of the
MMWG established the platform for AJCC for the Precision Medicine
Core (PMC) of the 8 th Edition of the AJCC Cancer Staging Manual, which is envisioned to continue and expand as a service to the oncology community. 18, 19 In this article, we provide a detailed catalog and evaluation of publicly available colorectal cancer prognostication tools.
| MATERIALS AND METHODS

| Search strategy and selection criteria
Prognostication tools were identified and documentation on their development and validation gathered using three strategies: 1) A search of the peer-reviewed published literature (including a systematic literature review and cited reference search); 2) A search of the web-based scientific community; and 3) Correspondence with individual tool developers when a web-based tool had no corresponding scientific journal article or technical report.
The search strategy was executed in OVID Medline, OVID Embase and HealthStar from Jan 1, 1996 to October 6th, 2015. Medical subject headings (MeSH) did not exist for prognostication tools and so a combination of alternate headings and key words were used following consultation with a scientific librarian. Each set of search terms was modified for the specific search engine. For example, the following search terms were used in Medline: "models, statistical/," "prognosis," "predict* model*," "nomogram/," "prognos* model*," and "colorectal neoplasm/." The searches were limited to English language. Clinically relevant tools originally published prior to 1996 were also included, but these were identified through validation articles found in the systematic literature review. Seemingly eligible studies were excluded if they met any of the following a priori exclusion criteria: 1) assessment of the prognostic impact of a single factor (unless it was updating the accuracy of an existing prognostic tool); 2) inappropriate analytic purpose (eg, multivariate modeling not aimed at prognostication, application of novel statistical methods); 3) not specific to colorectal cancer patients; 4) not original data/research (eg, editorial, review) or 5) the outcome was not survival. Studies reporting on genomic classifiers built entirely using gene expression data were not the focus of the review and were excluded.
Prognostication tools in this paper include those developed to estimate the probability of survival at a particular point along the disease trajectory (eg, at diagnosis, following treatment) or for the purpose of using a survival probability to inform treatment decisionmaking. Eligible survival end-points included all time-to-death analyses (eg, overall survival, cause-specific survival, relative survival), as well as vital status analyses (eg, probability of death at 5-years post-diagnosis).
Generally speaking, some form of statistical model underlies most prognostication tools, and we use the terms prognostication tool and prognostication model interchangeably. A single reviewer (AM)
assessed the titles and abstracts of citations for inclusion. At the beginning, a second reviewer evaluated a random sample of 20 citations to evaluate reliability. Percent agreement was 85%. The first reviewer was conservative and included more articles at the abstract phase than the second reviewer. These differences were easily resolved, and a discussion of discordant decisions determined that the rules for inclusion and exclusion were being applied consistently. A cited reference search using Web of Science was performed. This was implemented to decrease the probability of missing a relevant article.
These peer-reviewed literature search strategies to identify prognostic tools in colorectal cancer were supplemented by a Google web-based search. Search terms included: "clinical prediction tool cancer," "online calculator cancer," and "nomogram cancer." The AJCC contacted tool developers for details on tool development if a tool identified in the Google search did not have a supporting article in the peer-reviewed literature and a technical document was not publicaly available.
| Data abstraction
A detailed report on data abstraction form development and key definitions was published previously. 16, 20, 21 The data abstracted allowed an evaluation of tool development and validation methodology and clinical relevance. The final criteria include all key elements described by the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) guidelines 20, 21 and the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) checklist. 22 Clinical relevance was informally assessed by considering the prognostic factors' relevance to the clinical population and to the question addressed by the tool, and by considering the format of the tool (whether or not the equation was provided, usability in a clinical setting). General descriptive information such as study design, study population characteristics and outcome measurement were abstracted, as well as specific details on tool development (statistical modeling decisions, candidate variable selection) and validation (internal validation methods, measures of model predictive accuracy).
| Summary
Key tool development and validation terminology are reported elsewhere. 16, 20, 21 cancer, reported across 63 articles. Two articles reported on the development of two tools each. 40, 58 Eighteen articles contained external validations only. [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] One article updated two tools with additional prognostic information. 76 We did not identify any articles evaluating the effectiveness or implementation of tools in clinical practice. Documentation in the peer-review literature was not available for six prediction tools.
Correspondence with tool developers added technical documentation for two of those tools, and we were told that the remaining four were pending publication in the peer-review literature. All included prognostication tools were created using data collected for a purpose other than the development of a clinical prediction tool (Table 1) . Three tools were developed using data from prospective cohort studies designed with the purpose of investigating prognostic factors, and six others from data collected for one or more randomized controlled trials that were not initially designed to create and/or evaluate a clinical outcome prediction tool. Seventeen tools (32%) were developed using data on cancer populations in the United
| Tool development methods
States, eleven from Japan (21%), five from the United Kingdom (9%) and four each from France and Germany. In the 47 studies that reported colorectal case selection methods, 18 accrued data on patients from multiple institutions and 26 studies used data from a 
| Populations and prognostic factors
The populations addressed by each prognostication tool are described in Table 4 summarizes the assessments of internal and external validity. 
| Internal validity
| External validity
Half of the tools (27/53) did not have an evaluation of external validity (predictive accuracy in an independent sample separate from the one used for tool development) ( Table 4) . Seventy-nine assessments of external validity were performed on 26 tools by 33 studies, including those studies that both developed and validated a tool in the same 
Methodological criterion N (%)
Prognostic factor selection method Literature-based/clinical reasoning 7 (13) Screened using univariable analysis 12 (23) Available in existing dataset 2 (4)
Method not specified 32 (60) Methods for handling missing data separate populations. 54 The predictive accuracy of seven other tools was evaluated in at least three validation populations. 37, 38, 45, 52, 56, 58, 73 Of the 26 tools with some evaluation of external validity, 22 had at 
| DISCUSSION
This study summarized available information on 53 colorectal cancer prognostication tools identified from the peer-reviewed literature and web-based resources. These tools were most commonly intended to help inform clinical management decisions in stage IV patients with liver metastases. There were considerable differences in the prognostic factors included in tools designed to prognosticate in similar clinical sub-populations (eg, within tools for patients with liver metastases). In many cases, tool development methodology was incompletely reported or inadequate. A large number of internal and external validity assessments were performed; however, the majority did not adhere to recommended guidelines for appropriate statistical methodology. 20, 21 It is apparent that a framework for moving the science of prognostic tool development and validation forward, as well as its clinical application in oncology, is still needed in order to address the deficiencies highlighted in this systematic review. The systematic problems identified in the methods used to develop and validate colorectal cancer prognostication tools support the findings of other authors, [92] [93] [94] [95] and call for action in the improvement of prognostic tools in oncology. Over 50% of the tools in this review categorize patients into risk groups rather than providing individual probability estimates of survival, decreasing the accuracy for the individual patient. 21 Only 10% of studies with internal validity assessments used bootstrapping, the recommended method for evaluating internal validity. Although 79 external validation exercises were performed, they evaluated a subset of the prognostic tools developed, and half of tools remained with no assessment of generalizability. In addition, 50% of the internal and external validations performed did not adhere to best practices for evaluating predictive performance and did not include an evaluation of calibration or discrimination. The TRIPOD guidelines, published early in 2015,
were designed to assist clinicians and scientists in reporting clinical prediction tool studies. However, it is still too early to measure the impact this reporting guideline will have on the quality of future prognostic tool work in oncology. 20, 21 This study also provided an in depth look at the clinical populations and of which were not included within any of the included tools in our review. 96 In tools designed for non-metastatic patients, the inclusion of clinically significant prognostic factors summarized in the AJCC 7th
Edition of the Staging Manual, such as tumor regression grade, serum CEA or tumor deposits were not universal across all prognostic tools reviewed. 4 We have reported similar heterogeneity in prognostic information across prognostic tools in lung cancer 16 and melanoma. Advances in our ability to understand colorectal cancer will necessitate weighing their added outcome prediction value to existing, affordable, baseline prognostic tools in the future. This systematic literature review has a number of limitations. Our review may underestimate the number of existing prediction tools designed for survival in colorectal cancer, given the lack of literature search terms at the time to identify relevant studies. However, to account for this both a cited reference search and web-based resources search were performed to widen the net and capture all relevant tools and documentation. The review was also restricted to English language only studies, which may create a language reporting bias. However, the tools included in the study appeared to be developed and validated across a variety of countries and populations.
Finally, we did not include tools developed solely using genomic data, as we considered these outside the scope of the review. Therefore, the results of this review many not be representative of the methods and relevance of studies carried out in that area. system itself. The AJCC PMC has taken the first step to assuring that existing meritorious tools are made known to the community by establishing the criteria for AJCC endorsement and evaluating tools in major disease areas according to these guidelines. 18, 19 The AJCC intends to continue to play a leadership role in the evaluation, development, and promotion of high-quality prognostication tools in coordination with other authoritative groups such as the PROGnosis RESearch Strategy (PROGRESS) Partnership. 13 The evaluation of prognostic models has been incorporated into the 8th Edition of the staging manual. 18 Overall, prognostication tools are pervasive in colorectal cancer and may be particularly useful in clinical management when the outcome is uncertain. Guidance in the future direction of prognostication tool development and validation in colorectal cancer is needed.
Moving forward, many key clinical and methodological issues in the development, validation, and clinical usability need to be addressed.
However, addressing statistical and methodological concerns alone will not improve this research area, until consideration is given to the practical strengths and limitations of the literature. We need to build capacity and infrastructure to perform optimal prognostic tool research to realize the potential benefit of these tools for the future. 13, 20, 21 Collaborative, primary research grants with the objective of developing useful prognostic tools using prospectively collected data, and that include an appropriate assessment of internal and external validity, as well as the evaluation of impact on decisionmaking will be critical to improving the quality of prognostic tools available for use in colorectal cancer.
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